| Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation. | |
| | |
MedLine Citation:
|
PMID: 16983347 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In order to define genetic determinants of primary and metastatic melanoma cell susceptibility to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), we have applied oligonucleotide microarrays to TRAIL-sensitive primary T1 cells and TRAIL-resistant metastatic G1 cells treated or not with TRAIL. T1 and G1 cells are isogenic melanoma cell subclones. We examined 22 000 spots, 4.2% of which displayed differential expression in G1 and T1 cells. Cell susceptibility to TRAIL-mediated apoptosis was found to be correlated with gene expression signatures in this model. Some of the differentially expressed genes were identified as involved in ATP-binding and signaling pathways, based on previously published data. Further analysis provided evidences that c-kit was overexpressed in G1 cells while it was absent in T1 cells. The c-kit inhibitor, imatinib, did not restore TRAIL sensitivity, excluding a role for c-kit in TRAIL resistance in G1 cells. Surprisingly, imatinib inhibited cell proliferation and TRAIL-mediated apoptosis in melanoma cells. We investigated the possible involvement of several molecules, including c-ABL, platelet-derived growth factor receptor (PDGFR), cellular FADD-like interleukin-1 alpha-converting enzyme-like inhibitory protein (c-FLIP)(L/S), Fas-associated DD kinase, p53, p21(WAF1), proteins of B-cell leukemia/lymphoma 2 (Bcl-2) family and cytochrome c. Imatinib did not modulate the expression or activation of its own targets, such as c-ABL, PDGFRalpha and PDGFRbeta, but it did affect the expression of c-FLIP(L), BCL2-associated X protein (Bax) and Bcl-2. Moreover, c-FLIP(L) knockdown sensitized T1 cells to TRAIL-mediated apoptosis, with a sensitivity similar to that of cells previously treated with imatinib. More notably, we found that the resistance to TRAIL in G1 cells was correlated with constitutive c-FLIP(L) recruitment to the DISC and the inhibition of caspase 8, 3 and 9 processing. Moreover, c-FLIP(L) knockdown partly restored TRAIL sensitivity in G1 cells, indicating that the expression level of c-FLIP(L) and its interaction with TRAIL receptor2 play a crucial role in determining TRAIL resistance in metastatic melanoma cells. Our results also show that imatinib enhances TRAIL-induced cell death independently of BH3-interacting domain death agonist translocation, in a process involving the Bax:Bcl-X(L) ratio, Bax:Bcl-X(L)/Bcl-2 translocation, cytochrome c release and caspase activation. Our data indicate that imatinib sensitizes T1 cells by directly downregulating c-FLIP(L), with the use of an alternative pathway for antitumor activity, because PDGFRalpha is not activated in T1 cells and these cells do not express c-kit, c-ABL or PDGFRbeta. Caspase cascade activation and mitochondria also play a key role in the imatinib-mediated sensitization of melanoma cells to the proapoptotic action of TRAIL. |
| | |
Authors:
|
A Hamaï; C Richon; F Meslin; F Faure; A Kauffmann; Y Lecluse; A Jalil; L Larue; M F Avril; S Chouaib; M Mehrpour |
Related Documents
:
|
17180097 - Inactivation of retinoblastoma gene product rb or an rb-related protein by sv40 t antig... 20576107 - Chemotherapeutic drugs sensitize human renal cell carcinoma cells to abt-737 by a mecha... 10597317 - Latent membrane protein 1 associated signaling pathways are important in tumor cells of... 12785167 - Expression of bcl-2 oncoprotien in oral squamous cell carcinoma--an immunohistochemical... 9211887 - Cell-specific expression of the glucose-dependent insulinotropic polypeptide gene in a ... 19711917 - Antiproliferative activity and cytotoxicity of solanum jamesii tuber extracts on human ... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2006-09-18 |
Journal Detail:
|
Title: Oncogene Volume: 25 ISSN: 0950-9232 ISO Abbreviation: Oncogene Publication Date: 2006 Dec |
Date Detail:
|
Created Date: 2006-12-07 Completed Date: 2007-01-16 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 8711562 Medline TA: Oncogene Country: England |
Other Details:
|
Languages: eng Pagination: 7618-34 Citation Subset: IM |
Affiliation:
|
INSERM, U753, Laboratoire d'Immunologie des Tumeurs Humaines: Interaction effecteurs cytotoxiques-système tumoral, Institut Gustave Roussy PR1 and IFR 54, Villejuif, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
pharmacology* Apoptosis / drug effects* Caspases / metabolism* Cell Culture Techniques Cell Line, Tumor Cell Proliferation / drug effects Enzyme Activation Gene Expression Profiling Humans Melanoma / genetics, metabolism, pathology* Neoplasm Metastasis / genetics, pathology Oligonucleotide Array Sequence Analysis Piperazines / pharmacology* Proto-Oncogene Proteins c-bcl-2 / metabolism* Proto-Oncogene Proteins c-kit / metabolism Pyrimidines / pharmacology* Receptors, TNF-Related Apoptosis-Inducing Ligand / metabolism Recombinant Proteins / pharmacology TNF-Related Apoptosis-Inducing Ligand / pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Piperazines; 0/Proto-Oncogene Proteins c-bcl-2; 0/Pyrimidines; 0/Receptors, TNF-Related Apoptosis-Inducing Ligand; 0/Recombinant Proteins; 0/TNF-Related Apoptosis-Inducing Ligand; 0/TNFSF10 protein, human; 152459-95-5/imatinib; EC 2.7.10.1/Proto-Oncogene Proteins c-kit; EC 3.4.22.-/Caspases |
| Comments/Corrections | |
Erratum In:
|
Oncogene. 2007 Feb 22;26(8):1256 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination.
Next Document: Modern computational approaches for analysing molecular genetic variation data.